CliffBio
small molecule

TYZEKA

TELBIVUDINE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameTYZEKA
Active ingredientTELBIVUDINE
Strength600MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2006
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.